# OnCo record retinal-and-eye-effects-on-fgfr-mek-and-alk-inhibitors (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/retinal-and-eye-effects-on-fgfr-mek-and-alk-inhibitors/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "retinal-and-eye-effects-on-fgfr-mek-and-alk-inhibitors" ;
  schema:name "Retinal and visual side effects of FGFR, MEK and ALK inhibitors and other targeted drugs: eye examinations and dose rules"@en ;
  schema:alternateName "FGFR inhibitor retinopathy"@en, "MEK inhibitor retinopathy"@en, "MEKAR"@en, "central serous retinopathy on erdafitinib"@en, "retinal pigment epithelial detachment"@en, "RPED"@en, "serous retinal detachment on pemigatinib"@en, "retinal vein occlusion on MEK inhibitors"@en, "crizotinib visual disturbance"@en, "camizestrant photopsia"@en, "Datroway eye care"@en, "tamoxifen and cataract"@en, "Amsler grid on Balversa"@en ;
  schema:description "Some targeted cancer drugs can affect the back of the eye or your sight: FGFR inhibitors (erdafitinib, pemigatinib, futibatinib), MEK inhibitors (trametinib, binimetinib, cobimetinib, selumetinib), crizotinib and others. Most of their labels set eye checks and rules for pausing or lowering the dose. Tell your team straight away about any change in your sight."@en ;
  schema:url <https://onco.cc/protocols/retinal-and-eye-effects-on-fgfr-mek-and-alk-inhibitors/> ;
  schema:dateModified "2026-11-18"^^xsd:date ;
  onco:related <https://onco.cc/protocols/eye-care-with-ocular-toxic-antibody-drug-conjugates/>, <https://onco.cc/protocols/irae-ocular/>, <https://onco.cc/protocols/hyperphosphataemia-on-fgfr-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/erdafitinib/>, <https://onco.cc/drugs/pemigatinib/>, <https://onco.cc/drugs/futibatinib/>, <https://onco.cc/drugs/trametinib/>, <https://onco.cc/drugs/binimetinib/>, <https://onco.cc/drugs/cobimetinib/>, <https://onco.cc/drugs/selumetinib/>, <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/drugs/brigatinib/>, <https://onco.cc/drugs/camizestrant/>, <https://onco.cc/drugs/datopotamab-deruxtecan/> ;
  onco:terms <https://onco.cc/terms/ocular-toxicity/> .
